Can Ondansetron Be Given Sublingually to Children Under Two Years?
No, ondansetron should not be administered sublingually to children under two years of age, as the FDA has not established safety and effectiveness for oral ondansetron (including oral dissolving tablets) in pediatric patients younger than 4 years old. 1
FDA-Approved Age Restrictions
The FDA drug label explicitly states that "the safety and effectiveness of orally administered ondansetron have been established in pediatric patients 4 years and older for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy" 1. This means:
- Children under 4 years: No established safety or efficacy data for oral formulations (including sublingual/oral dissolving tablets)
- Children 4 years and older: Approved for use in cancer chemotherapy-induced nausea/vomiting only
- For gastroenteritis: Not FDA-approved for any pediatric age group
Available Formulations and Routes
The FDA label and guidelines reference several ondansetron formulations 2:
- Oral dissolving tablets (ODT)
- Oral soluble film
- Oral solution
- Intravenous (IV) administration
While oral dissolving tablets are designed to dissolve in the mouth, this does not constitute FDA approval for children under 4 years, regardless of the route of administration.
Clinical Practice Reality vs. FDA Approval
Important caveat: Despite lack of FDA approval for children under 2 years, research demonstrates ondansetron is widely used off-label in emergency departments for gastroenteritis in younger children:
- Studies have enrolled children as young as 6 months 3, 4
- One study included children aged 3 months to 10 years 5
- Research shows efficacy in reducing vomiting and IV fluid requirements in these younger age groups 3, 4, 6
However, off-label use does not change the FDA's position that safety and effectiveness have not been formally established in children under 4 years.
Practical Considerations for Sublingual Administration
If ondansetron is being considered off-label for a child under 2 years:
- Oral dissolving tablets (ODT) were better tolerated than oral solution in children 3 months to 10 years, with significantly less early vomiting (2.7% vs 9.5%) 5
- ODT formulations dissolve rapidly in the mouth without requiring water
- Dosing: Weight-based at 0.15 mg/kg has been studied 4, 7
- The dose range of 0.13-0.26 mg/kg showed similar efficacy without increased side effects 7
Bottom Line
Ondansetron sublingual/oral dissolving tablets are not FDA-approved for children under 4 years of age. While extensively used off-label in emergency settings for children as young as 6 months with gastroenteritis, this represents off-label prescribing that should only be undertaken with full awareness of the lack of formal safety and efficacy data in this age group, appropriate informed consent, and careful clinical judgment weighing risks versus benefits of dehydration.